Simple Blood Test Identifies Women in Labor at Risk for Preeclampsia
By LabMedica International staff writers Posted on 22 Oct 2024 |

Between 5% and 10% of pregnant women develop preeclampsia, a leading cause of maternal death, characterized by sudden high blood pressure and protein in the urine. Black women are 60% more likely to develop preeclampsia compared to white women and are also more likely to experience severe outcomes, including death or kidney damage. A simple blood test may now assist doctors in identifying women in labor who are at risk for preeclampsia, enabling them to take preventive measures.
Researchers have discovered that doctors can predict a woman’s risk of developing preeclampsia by calculating the ratio of two blood proteins—fibrinogen and albumin—measured in routine blood tests conducted when women in labor arrive at the hospital. Fibrinogen plays a role in blood clotting and inflammation, while albumin is essential for maintaining fluid balance and transporting hormones, vitamins, and enzymes throughout the body. Both proteins can be disrupted in cases of preeclampsia, with fibrinogen levels potentially elevated, albumin levels reduced, or both occurring simultaneously. There is no universally recognized normal value for this fibrinogen-to-albumin ratio (FAR), which can vary from 0.05 to 1 or higher. Elevated FAR values are frequently associated with increased inflammation, infection, or serious health issues, and higher FAR readings raise greater concern. This trend has been consistently observed when using FAR to assess other inflammatory conditions, such as rheumatoid arthritis, cardiovascular diseases, and inflammatory bowel disease.
Although preeclampsia can develop as early as the 20th week of pregnancy, the study conducted by researchers at the Icahn School of Medicine at Mount Sinai (New York, NY, USA) focused on identifying women at risk for preeclampsia upon their admission to the hospital during labor. The researchers analyzed the records of 2,629 women who gave birth between 2018 and 2024, including 1,819 who did not have preeclampsia, 584 who had preeclampsia with mild features (such as blood pressure of 140/90 mm Hg or higher without significant organ damage), and 226 who presented with preeclampsia with severe features (including blood pressure of 160/110 mm Hg or higher and signs of organ damage like severe headaches, elevated liver enzymes, visual disturbances, low platelet count, or kidney impairment). The researchers found that women with a higher FAR were more likely to develop preeclampsia than those with a lower FAR.
Research presented at the ANESTHESIOLOGY 2024 annual meeting indicated that the predicted likelihood of developing any degree of preeclampsia was 24% for patients with a FAR of at least 0.1 upon hospital admission, increasing to over 41% when the FAR exceeded 0.3. If a woman in labor is found to be at elevated risk for preeclampsia based on the FAR and other clinical indicators—such as being older than 35, having chronic high blood pressure, or being obese—obstetricians and anesthesiologists can implement additional precautions to minimize risk and ensure stable blood pressure and fluid levels. For instance, they may order more frequent blood pressure monitoring or laboratory tests. If the FAR suggests that a woman is at risk for severe symptoms of preeclampsia, an epidural for pain management can be administered early to mitigate potential risks.
“While FAR has been associated with other inflammatory conditions, its specific application to preeclampsia and preeclampsia with severe symptoms has not been reported in a group this large and racially diverse,” said Lucy Shang, B.A., lead author of the study and a medical student at the Icahn School of Medicine at Mount Sinai. “Our study shows that FAR can be a predictive tool that gives anesthesiologists and obstetricians a new method for assessing a laboring mom’s risk of developing preeclampsia when they are admitted to the hospital.”
Latest Molecular Diagnostics News
- Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD
- First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis
- New Molecular Label to Help Develop Simpler and Faster Tuberculosis Tests
- Biomarker Discovery Paves Way for Blood Tests to Detect and Treat Osteoarthritis
- Liquid Biopsy Assay Detects Recurrence in CRC Patients Prior to Imaging
- Ultra Fast Synovial Fluid Test Diagnoses Osteoarthritis and Rheumatoid Arthritis In 10 Minutes
- Genetic-Based Tool Predicts Survival Outcomes of Pancreatic Cancer Patients
- Urine Test Diagnoses Early-Stage Prostate Cancer
- New Genetic Tool Analyzes Umbilical Cord Blood to Predict Future Disease
- Spinal Fluid Biomarker for Parkinson’s Disease Offers Early and Accurate Diagnosis
- Revolutionary Blood Test Detects 30 Different Types of Cancers with 98% Accuracy
- Simple Blood Test Better Predicts Heart Disease Risk
- New Blood Test Detects 12 Common Cancers Before Symptoms Appear
- Blood Test Could Predict Relapse of Autoimmune Blood Vessel Disease
- First-of-its-Kind Blood Test Detects Trauma-Related Diseases
- Key Gene Identified in Common Heart Disease Unlocks Life-Saving Diagnostic Potential
Channels
Clinical Chemistry
view channel
AI-Powered Blood Test Accurately Detects Ovarian Cancer
Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more
Automated Decentralized cfDNA NGS Assay Identifies Alterations in Advanced Solid Tumors
Current circulating cell-free DNA (cfDNA) assays are typically centralized, requiring specialized handling and transportation of samples. Introducing a flexible, decentralized sequencing system at the... Read moreMass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read moreHematology
view channel
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Molecular Stool Test Shows Potential for Diagnosing TB in Adults with HIV
Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, led to 1.25 million deaths in 2023, with 13% of those occurring in people living with HIV. The current primary diagnostic method for... Read more
New Test Diagnoses Bacterial Meningitis Quickly and Accurately
Bacterial meningitis is a potentially fatal condition, with one in six patients dying and half of the survivors experiencing lasting symptoms. Therefore, rapid diagnosis and treatment are critical.... Read morePathology
view channel
Groundbreaking Chest Pain Triage Algorithm to Transform Cardiac Care
Cardiovascular disease is responsible for a third of all deaths worldwide, and chest pain is the second most common reason for emergency department (ED) visits. With EDs often being some of the busiest... Read more
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read moreTechnology
view channel
Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more